

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : A61K 31/70, C12N 15/11	A2	(11) International Publication Number: WO 93/13740 (43) International Publication Date: 22 July 1993 (22.07.93)
(21) International Application Number: PCT/US92/11202 (22) International Filing Date: 31 December 1992 (31.12.92) (30) Priority data: 07/815,393 31 December 1991 (31.12.91) US (60) Parent Application or Grant (63) Related by Continuation US 07/815,393 (CIP) Filed on 31 December 1991 (31.12.91) (71) Applicant (for all designated States except US): WORCESTER FOUNDATION FOR EXPERIMENTAL BIOLOGY [US/US]; 222 Maple Avenue, Shrewsbury, MA 01545 (US).	(72) Inventors; and (75) Inventors/Applicants (for US only) : RAPAPORT, Eliezer [US/US]; 142 Payson Road, Belmont, MA 02178 (US). ZAMECNIK, Paul, C. [US/US]; 29 LeBeaux Drive, Shrewsbury, MA 01545 (US). (74) Agent: SARUSSI, Steven, J.; Allegretti & Witcoff, Ltd., 10 South Wacker Drive, Chicago, IL 60606 (US). (81) Designated States: CA, JP, KR, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>Without international search report and to be republished upon receipt of that report.</i>	
(54) Title: ANTIPARASITIC OLIGONUCLEOTIDES ACTIVE AGAINST DRUG RESISTANT MALARIA (57) Abstract The invention provides methods and materials for antisense oligonucleotide therapy against active pathogenic infection by drug resistant or drug sensitive pathogens, including <i>Plasmodium falciparum</i> .		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NL	Netherlands
BE	Belgium	GN	Guinea	NO	Norway
BF	Burkina Faso	GR	Greece	NZ	New Zealand
BG	Bulgaria	HU	Hungary	PL	Poland
BJ	Benin	IE	Ireland	PT	Portugal
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SK	Slovak Republic
CI	Côte d'Ivoire	LJ	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	MC	Monaco	TG	Togo
DE	Germany	MG	Madagascar	UA	Ukraine
DK	Denmark	ML	Mali	US	United States of America
ES	Spain	MN	Mongolia	VN	Viet Nam
FI	Finland				

ANTIPARASITIC OLIGONUCLEOTIDES ACTIVE
AGAINST DRUG RESISTANT MALARIA

BACKGROUND OF THE INVENTION

1. Field of the Invention

5 The invention relates to the treatment of
pathogenic infections through the use of
chemotherapeutic agents. More specifically, the
invention relates to the treatment of infections by
pathogens having resistance to conventional
10 chemotherapeutic agents, such as drug resistant
malaria.

2. Summary of the Related Art

Malaria is one of the most widespread of human
pathogenic diseases, accounting for high morbidity and
15 mortality, particularly in Southeast Asia, Africa and
South America. Partial success in the eradication of
this disease has been obtained by control of mosquito
populations, institution of vaccination programs and
treatment with antimalarial drugs. However, multiple
20 resistance to antimalarial drugs has been largely
responsible for a resurgence in the incidence and

-2-

severity of this disease in recent years. Oaks et al., "Malaria, Obstacles and Opportunities, A report of the committee for the study on malaria prevention and control: status review and alternative strategies", Division of International Health, Institute of Medicine, National Academy Press (1991) discloses up to date information about the disease, its clinical aspects, its etiological agent and vector, as well as current difficulties in controlling the disease and other aspects of the present spread of malaria.

Malaria is just one of a variety of human parasitic infections having increased prevalence worldwide. Webster, in Section X of The Pharmacological Basis of Therapeutics, (Gilman et al., Eds.) Eight Edition, Pargamm Press (1991) discusses several factors responsible for the increase in parasitic infections generally, including population growth and crowding, poor sanitation, inadequate control of parasite vectors, introduction of agricultural water control systems, increased population migration, and development of resistance to agents used for chemotherapy or for control of

-3-

vectors. In fact, acquired drug resistance has become a major public health problem concerning a variety of infectious pathogens, including bacteria and viruses.

Laboratory techniques for in vitro screening of
5 antimalarial drugs are well known in the art. Such techniques utilize the asexual erythrocytic cycle of Plasmodium falciparum in cultured human red blood cells. Trager and Jensen, Science 193: 673-675 (1976) discloses continuous maintenance of human malarial
10 parasites in vitro. Desjardins et al., Antimicrobial Agents and Chemotherapy 16: 710-718 (1979) discloses a method of quantitative assessment of the in vitro antimalarial activity of drugs, using a semiautomated microdilution technique. Chulay et al., Experimental
15 Parasitology 55: 138-146 (1983) discloses a method of assessing in vitro growth of P. falciparum by measuring incorporation of [³H]-hypoxanthine. Lambros and Vanderburg, Journal of Parasitology 65: 418-420 (1979) discloses procedures for the synchronization of
20 the erythrocytic stages of P. falciparum in culture, which allows mechanistic interpretation of the activities of antimalarial drugs.

These in vitro systems have been shown to be

-4-

predictive of the clinical outcome for a variety of agents in the treatment of human malaria. Bitonti et al., Science 242: 1301-1303 (1988) discloses correct in vitro prediction of reversal of chloroquine resistance in P. falciparum by desipramine. Martin et al., Science 235: 899-901 (1987) discloses correct in vitro prediction of chloroquine resistance in P. falciparum by verapamil.

A variety of antimalarial agents have been developed. These agents act on the asexual erythrocytic stages as schizonticidal agents. Chloroquine, quinine, quinidine, mefloquine and pyrimethamine are weak bases that accumulate to high levels in the acidic food vacuoles of the plasmodial parasite and interfere with a variety of cellular processes of the parasite, as well as with its interaction with its erythrocytic host. These agents can be used in conjunction with sulfonamides, sulfones, or tetracyclines. Specific inhibition of the malarial parasite can be attempted through exploitation of a variety of potential targets. Holder et al., Nature 317: 270-273 (1985) discloses the primary structure of the precursor to the three

SUBSTITUTE SHEET

-5-

major surface antigens of the P. falciparum merozoites, the form of the malarial parasite that breaks out of the erythrocyte and invades uninfected erythrocytes. Hadley et al., Ann. Rev. Microbial. 40: 451-477 (1986) discusses the cellular and molecular basis of the invasion of erythrocytes by malaria parasites. Queen et al., Antimicrobial Agents and Chemotherapy 34: 1393-1398 (1990) discusses in vitro susceptibility of P. falciparum to compounds that inhibit nucleotide metabolism, a susceptibility grounded in the exclusive reliance of P. falciparum on a salvage pathway for obtaining purine bases and nucleosides, and upon de novo synthesis of pyrimidines. Ferone et al., Molecular Pharmacology 5: 49-59 (1969) and Hitchings and Burchell, Advances in Enzymology 27: 417-468 (1967) teach that pyrimethamine inhibits protozoal dihydrofolate reductase, and thus de novo pyrimidine biosynthesis, to a much greater extent than it inhibits the mammalian dihydrofolate reductase of the host, thus making pyrimethamine a useful chemotherapeutic against malaria.

Unfortunately, drugs such as pyrimethamine are rendered ineffective by the global emergence of

-6-

resistant strains. Peterson et al., Proc. Natl. Acad. Sci. USA 85: 9114-9118 (1988) discloses that a point mutation in dihydrofolate reductase-thymidilate synthase confers resistance to pyrimethamine in *falciparum* malaria. Martin et al., Science 235: 899-901 (1987) teaches that chloroquine resistance in *P. falciparum* arises from the acquired ability of the parasite to prevent intracellular accumulation of the cytotoxic drug. Multiple drug resistance poses a serious clinical problem for treatment of malaria only with the malarial strain *P. falciparum*. However, this species accounts for over 85% of the cases of human malaria and for most of the mortality resulting from this disease. Shanzer et al., Proc. Natl. Acad. Sci. USA 88: 6585-6589 (1991) teaches that the resistant parasites maintain their cross-resistance towards a variety of drugs in vitro, as well as in vivo, thus enabling investigators to attempt to identify the biochemical mechanisms underlying drug resistance, and to try to overcome such resistance by innovative chemotherapeutic strategies.

There is, therefore, a need for novel chemotherapeutic approaches for the treatment of drug

-7-

resistant parasites, such as *P. falciparum*. Such approaches can be useful also in the treatment of other protozoan infections, including leishmaniasis and trypanosomiasis.

5 Exogenous administration of synthetic oligonucleotides is an emerging approach for inhibiting a variety of infectious agents. Zamecnik and Stephenson, Proc. Natl. Acad. Sci. USA 75: 280-284 (1978) discloses inhibition of replication and gene
10 expression of Rous Sarcoma Virus (RSV) by exogenous oligonucleotides in tissue cultures of chick embryo fibroblasts, thereby preventing transformation of fibroblasts into sarcoma cells. Stephenson and Zamecnik, Proc. Natl. Acad. Sci. USA 75: 285-288
15 (1978) teaches that the same oligonucleotide inhibits cell-free synthesis of proteins specified by the RSV 305 RNA in a reticulocyte system. Zamecnik et al., Proc. Natl. Acad. Sci. USA 83:4143-4146 (1986) discloses inhibition of replication of human
20 immunodeficiency virus (HIV) in in vitro screening systems, using synthetic oligonucleotides that are complementary to a variety of conserved regions of the

-8-

HIV genome. The use of modified internucleotide bridging phosphates resulted in a 10 to 100-fold decrease in the 50% inhibitory concentration (IC_{50}) for in vitro HIV replication. Matsukura et al., Proc. Natl. Acad. Sci. USA 84: 7706-7710 (1987) discloses this effect using oligonucleotide phosphorothioates. Agrawal et al., Proc. Natl. Acad. Sci. USA 85: 7079-7084 (1988) shows a similar effect for oligonucleotide phosphorothioates and phosphoroamidates. Sarin et al., Proc. Natl. Acad. Sci. USA 85: 7448-7451 (1988) discloses enhanced inhibition of HIV, using oligonucleotide methylphosphonates.

The use of exogenous oligonucleotides to inhibit retroviral infection, as disclosed in the above publications and in Goodchild et al., U.S. Patent No. 4,806,463, represents treatment of a latent or dormant condition, since the retroviral genome is integrated into the host cell genome and is expressed with the participation of host cellular enzymes and factors only after a significant latency period. In contrast, the treatment of malaria, other infectious parasitic diseases and acute viral and bacterial infections represents chemotherapy for active infections

-9-

requiring immediate treatment. Bzik, et al., Proc. Natl. Acad. Sci. USA 84: 8360-8364 (1987) teaches the nucleotide sequence of the P. falciparum dihydrofolate reductase-thymidilate synthase gene. However, recent
5 attempts at using exogenous oligonucleotides to inhibit synthesis of these proteins from P. falciparum mRNA in a cell free translation system have shown an absence of promise for this approach for the clinical treatment of malaria. Sartorius and Franklin, Nucleic
10 Acids Res. 19: 1613-1618 (1991) demonstrates a complete failure of oligonucleotides to inhibit protein synthesis in such a system, unless the oligonucleotides are pre-annealed to P. falciparum mRNA at an elevated temperature of 65°C for 5 minutes,
15 followed by a one hour cooling at 30°C. Moreover, even under these highly nonphysiological conditions a dramatically high concentration of 150-170µM was required for the 30-49 nucleotide oligomers to produce 50% inhibition. These results suggest that inhibition
20 of malarial protein synthesis by oligonucleotides will not be possible in vivo, where the host erythrocyte and the intraerythrocytic parasite are maintained at the body temperature of 37°C.

-10-

BRIEF SUMMARY OF THE INVENTION

The invention relates to the chemotherapeutic treatment of pathogenic infections. The invention provides methods and materials for antisense
5 oligonucleotide therapy for the treatment of active infections by human pathogens. The method according to the invention comprises administering oligonucleotides that inhibit the pathogenic infection. The method is equally effective in
10 treating drug resistant and drug sensitive pathogens. In particular, the method is highly effective against drug resistant and drug sensitive parasites, such as the malarial parasite. Oligonucleotides according to the invention are useful in the method of the
15 invention. Such oligonucleotides have inhibitory effects upon the pathogen. Preferably, the inhibitory effect of oligonucleotides according to the invention arises from such oligonucleotides having a nucleotide sequence that hybridizes under physiological
20 conditions to a vital gene of the pathogen, such as the P195 and dihydrofolate reductase-thymidilate synthase gene of Plasmodium falciparum. In some instances the inhibitory effect of oligonucleotides is

-11-

independent of any known complementarity to vital
genes of the pathogen. Oligonucleotides according to
the invention may be conventional
oligodeoxynucleotides, or may have one or more
5 modifications at internucleoside linkages or at either
end.

-12-

DETAILED DESCRIPTION OF THE SPECIFIC EMBODIMENTS

The invention relates to the chemotherapeutic treatment of active infections by pathogenic organisms. More particularly, the invention provides
5 methods and materials for the chemotherapeutic treatment of active infections by human pathogens. The method according to the invention is known as antisense oligonucleotide therapy. The materials according to the invention are oligodeoxynucleotides,
10 oligonucleotide phosphorothioates, other oligonucleotides having modified internucleotide linkages, and modified versions of oligodeoxynucleotides and oligodeoxynucleotide phosphorothioates, and other oligonucleotides having
15 modified internucleotide linkages. For example, "oligonucleotides", for purposes of the invention is intended to include oligonucleotides having phosphodiester phosphorothioate, phosphorodithioate, phosphoramidate, alkylphosphonate and/or
20 phosphotriester internucleotide linkages, as well as modifications at the bases and/or sugar molecules of the oligonucleotide. For purposes of the invention, the term oligonucleotide includes

-13-

oligoribonucleotides, oligodeoxyribonucleotides, and
oligoribonucleotides or oligodeoxyribonucleotides
having modified internucleoside linkages.

In a first aspect, the invention provides, for
5 the first time, methods for treating malaria using
antisense oligonucleotide therapy. Antisense
oligonucleotide therapy involves the provision to the
infected cells of oligonucleotides having a nucleotide
sequence that hybridizes under physiological
10 conditions to a target sequence, thereby interfering
with the physiological function of that target
sequence. In the case of malaria, two genetic targets
from Plasmodium falciparum were used. The first of
these was the P195 gene, which encodes the protein
15 precursor of three smaller proteins which are major
surface antigens of merozoites, and thus are required
for the development of plasmodial merozoites.
Merozoites are the form of the material parasite that
breaks out of the erythrocyte and invades uninfected
20 erythrocytes. The P195 sequences used included the
first 21 nucleotides of the open reading frame,
starting with the AUG start codon (P195-I), and an 18

SUBSTITUTE SHEET

-14-

nucleotide sequence encoding part of an alternate repeat of two tripeptide sequences occurring six and five times respectively in the protein sequence (P195-II). The second genetic target was the dihydrofolate reductase-thymidilate synthase gene, a gene essential to de novo pyrimidine synthesis. Malarial parasites rely exclusively on de novo synthesis of pyrimidine nucleotides, and are incapable of salvaging preformed pyrimidine bases or nucleosides. Consequently, interference with the physiological function of this enzyme is fatal to the malarial parasite.

Those skilled in the art will recognize that other oligonucleotides, having sequences that hybridize under physiological conditions to other portions of the P195 gene or the dihydrofolate reductase-thymidilate synthase gene will also be useful in the method of the invention, given the success of the oligonucleotides described above. In addition, this success will lead those skilled in the art to recognize that oligonucleotides having a nucleotide sequence that hybridizes under physiological conditions to any vital gene of the malarial parasite will satisfy the requirements of

-15-

this aspect of the invention. For purposes of the invention, a vital gene is any gene having a physiological function necessary to the replication or reproduction of the pathogen, such that interference
5 with its function by antisense oligonucleotides will impair the ability of the pathogen to replicate or reproduce.

In this aspect of the invention, antisense oligonucleotide therapy was found to be effective in
10 inhibiting malaria in vitro. However, the in vitro system used in these studies has been validated as a predictor of the clinical success of a variety of antimalarial agents. Thus, this aspect of the invention provides an effective method for inhibiting
15 malaria either in vitro, or in vivo. For in vivo treatment, oligonucleotides can be delivered by infusion, injection, oral provision, or topical application.

In a second aspect, the invention provides a
20 method for treating infections by pathogens that have acquired resistance to conventional chemotherapeutic agents. Conventional chemotherapeutic agents are

-16-

those well known agents that are commonly used to treat the particular pathogen in question. Resistance to chemotherapeutic agents can arise from mutations in the gene encoding the protein upon which the

5 chemotherapeutic agent acts. Alternatively, such resistance can arise from the pathogen being able to prevent intracellular accumulation of the cytotoxic drug. The method according to the invention overcomes both types of resistance, because oligonucleotides act

10 at the level of the gene or mRNA, rather than protein, and because they are not excluded from intracellular accumulation. In this aspect, it was found that the method according to the invention was equally effective against either chloroquine sensitive or

15 chloroquine resistant P. falciparum. Since chloroquine resistance in malaria is generally part of a broad cross-resistance to a variety of chemotherapeutic agents, the invention provides an effective method for overcoming drug resistance in

20 malaria. Moreover, Webster et al., in the Pharmacological Basis of Therapeutics, pp. 954-959 (1990) teaches that parasitic infections in man share many common features, and several antiparasitic

-17-

agents act against a variety of human parasites. In particular, Kouni, Biochemical Pharmacology 41: 815-820 (1991) demonstrates cross-effectiveness against schistosomiasis, malaria and trypanosomiasis. Thus

5 the invention provides methods for treatment that should be equally effective against either drug sensitive or drug resistant forms of a variety of parasites, including protozoa such as leishmania and trypanosoma, and nonprotozoa parasites, such as

10 schistosoma. Other conditions of particular interest for treatment by the method according to the invention include candidiasis, histoplasmosis, cryptococcus, blastomycosis, aspergillosis, sporotrichosis, dermatophytosis, coccidioidomycosis, typhus, Rocky

15 Mountain spotted fever, Chlamydia trachomatis infection, Lymphogranuloma venereum infection, amebiasis, Chagas' disease, toxoplasmosis, pneumocystosis, giardiasis, cryptosporidiosis, trichomoniasis, Pneumocystis carini infections,

20 ascariasis, filariasis, trichinosis, nematode infection and cestode infection, wherein the condition is caused by a drug resistant pathogen. Finally, the known mechanisms of drug resistance suggest that

-18-

oligonucleotides should be useful in methods for treatment that overcomes drug resistance generally. Drug resistance by other pathogens also generally relies upon either modification of the protein acted
5 upon by the drug, or upon the ability to prevent intracellular accumulation of the drug. Oligonucleotides are not rendered ineffective by these mechanisms. Thus, the invention provides a general method of treating drug resistant pathogens, including
10 drug resistant bacteria (e.g., tuberculosis) and viruses.

In a third aspect, the invention provides a method for treating malaria that is safer than existing methods. For example, chloroquine treatment
15 of malaria requires administration of concentrations of chloroquine approaching levels at which significant toxic side effects occur. In contrast, in the method according to the invention, 50% inhibition of malaria is observed at a concentration of oligonucleotide that
20 is over 50-fold lower than is required to produce toxic side effects in rats and mice. Those skilled in

-19-

the art will recognize that the effectiveness of oligonucleotides may be enhanced by co-treatment of the parasitic infection by oligonucleotides and conventional antimalarial chemotherapeutic agents, such as chloroquine, quinine, quinidine, mefloquine, or pyrimethamine, either with or without sulfonamides, sulfones, or tetracyclines. Such co-treatment should allow reduced doses of the existing chemotherapeutic agents to be used, thereby increasing safety.

10 In a fourth aspect, the invention provides oligonucleotides that are useful in the method according to the invention. Such oligonucleotides have nucleotide sequences that hybridize under physiological conditions with a vital gene of the
15 pathogen. Examples of such oligonucleotides are oligonucleotides having nucleic acid sequences that hybridize under physiological conditions with the P falciparum P195 or dihydrofolate reductase-thymidilate synthase genes. Such oligonucleotides are illustrated
20 by way of example in Table I. Oligonucleotides according to the invention may be conventional oligodeoxynucleotides, or may have one or more

-20-

internucleoside linkages in a modified form such as phosphorothioate, phosphorodithioate or phosphoramidate linkages. In a preferred embodiment, the oligonucleotide has phosphorothioate
5 internucleoside linkages. In addition, oligonucleotides according to the invention may have additional modifications, including the presence of chemical structures that confer resistance to degradation at either or both ends. In a preferred
10 embodiment, the oligonucleotide is rendered resistant to nucleolytic degradation, and hence more effective against malaria, due to the presence of a phosphorbutylamidate as the 3'-most internucleoside linkage.

15 In a fifth aspect, the invention provides novel oligonucleotides having antimalarial activity that appears to be independent of complementarity to any known vital gene of the malarial parasite. An example of such an oligonucleotide was synthesized as an
20 apparently random oligonucleotide having the nucleotide sequence 5'-CTTGGCAGCTGCGCGTGACAT-3'. The mechanism of the antimalarial activity of this

-21-

oligonucleotide is not understood.

Further preferred embodiments of the invention
will become apparent from the following examples,
which are intended to more fully illustrate the
5 invention, and not to limit its scope.

-22-

Example 1Synthesis of Oligodeoxynucleotides, Oligonucleotide
Phosphorothioates and Modifications Thereof

Synthesis and purification of oligonucleotides,
5 oligonucleotide phosphorothioates, and modified forms
of each was carried out according to the well known H-
phosphonate approach, as described in Agrawal et al.,
Proc. Natl. Acad. Sci. USA 86: 7790-7794 (1989). The
nucleotide sequences selected for such synthesis were
10 complementary to the 5' regions of the coding
sequences of the P. falciparum P195 and dihydrofolate
reductase-thymidilate synthase genes. The sequences
of these genes are set forth, respectively, in Holder
et al., Nature 317: 270-273 (1985) and in Bzik et al.,
15 Proc. Natl. Acad. Sci. USA 84: 8360-8364 (1987).
Apparently random oligonucleotide sequences were
synthesized for use as controls. The chemical
structure and target specificity of the synthetic
oligonucleotides are set forth in Table I₁ below.

-23-

Table I

Chemical Structure and Target Specificity of
Oligonucleotides Tested as Antimalarial Agents

<u>No.</u>	<u>Sequence, chemical structure and target sequence</u>
5	
PSI	5'-TAA AAA GAA TAT GAT CTT CAT-3' Oligodeoxynucleotide phosphorothioate complementary in sequence to the first 21 nucleotides of the open reading frame from the start codon of P195
10	
PSII	5'-AGC AAC TGA GCC ACC TGA-3' Oligodeoxynucleotide phosphorothioate complementary in sequence to the 18 nucleotide sequences in P195 coding for the first two tripeptide repeats
15	
PNII	5'-AGC AAC TGA GCC ACC TAG-3' Oligodeoxynucleotide phosphomorpholidate complementary in sequence to the same sequence in P195 as PSII
20	
POII	5'-AGC AAC TGA GCC ACC TGA-3' Oligodeoxynucleotide (phosphodiester internucleoside bond) complementary in sequence to the same sequence in P195 as PSII
25	
PSIII	5'-GTC GCA GAC TTG TTC CAT CAT-3' Oligodeoxynucleotide phosphorothioate having a sequence complementary to the first 21 nucleotides of the open reading frame of <i>Plasmodium falciparum</i> dihydrofolate reductase-thymidylate synthase gene starting with the start codon
30	
PSNIII	5'-GTC GCA GAC TTG TTC CAT CAT-3' Oligodeoxynucleotide phosphorothioate with the last 3' phosphodiester bond being a phosphorbutylamidate for the inhibition of exonuclease activity, having the same sequence as PSIII
35	

SUBSTITUTE SHEET

-24-

- RI 5'-CTT GGC AGC TGC GCG TGA CAT-3'
Oligodeoxynucleotide phosphorothioate of
apparently random sequence
- 5 RII 5'-ACC TTA TGT ATC ATA CAC ATG-3'
Oligodeoxynucleotide phosphorothioate of
apparently random sequence
- RIII 5'-AAA AAT ATT TAT TTT CTA A-3'
Oligodeoxynucleotide phosphorothioate of
apparently random sequence
- 10 RIV 5'-CGC GGC GGC CCG CGG CGC CGG-3'
Oligodeoxynucleotide phosphorothioate of
apparently random sequence

-25-

Example 2In Vitro Culture and Synchronization
of Plasmodium falciparum

The strains of P. falciparum used for assessment
5 of antimalarial activity of oligonucleotides were W2,
an Indochina clone exhibiting chloroquine resistance,
and D6, a chloroquine sensitive West African clone.
Both strains were isolated at the Walter Reed Army
Institute of Research, Washington D.C. Both strains
10 were cultured by a modification of the method of
Trager and Jensen, Science 193: 673-675 (1976).
Parasites were maintained in flasks in an atmosphere
of 4% oxygen, 6% carbon dioxide and 90% nitrogen in a
5-8% erythrocytic suspension in complete RPMI 1640
15 medium supplemented with 3mg/ml TES sodium salt,
2mg/ml glucose, 110µg/ml sodium pyruvate, 300µg/ml
glutamine, 5µg/ml hypoxanthine, 25µg/ml gentamicin and
10% human plasma at 37°C. Fresh type A, Rh positive
blood cells and human plasma were obtained from the
20 American Red Cross. Synchronization of parasites was
performed by treatment with D-sorbitol, according to
the well known method of Lambros and Vanderburg,
Journal of Parasitology 65: 418-420 (1979).

SUBSTITUTE SHEET

-26-

Example 3Assessment of the Antimalarial Activity of
Oligonucleotides

Nonsynchronous cultures of *P. falciparum* were
5 incubated for 72 hours, the last 48 hours in the
presence of oligonucleotides. Synchronized cultures
were grown in the presence of oligonucleotides,
beginning 24 hours after synchronization by D-sorbitol
treatment. Antimalarial activities were
10 quantitatively determined either by counting parasites
or by the incorporation of [³H]-hypoxanthine into acid
insoluble radioactivity, according to the method of
Chulay et al., Experimental Parasitology 55: 138-146
(1983).

15 For counting of parasites, parasitized
erythrocytes (0.5% to 1% parasitemia) were cultured in
48 well microculture plates (Gibco, Chagrin Falls,
Ohio) at 5% hematocrit in a total volume of 1ml per
well. Parasitemia levels were determined by counting
20 thin blood films ("smears"), fixed and stained with
Diff-Quick™ (Baxter, McGaw Park, Illinois). At least
1000 erythrocytes were counted. Parasites were
classified according to their developmental stage as

-27-

ring forms (R) without pigment, which is the first form after merozoite inversion of the erythrocyte, trophozoites (T) containing pigment and a single nucleus, and schizonts (S), which are developmental
5 forms with more than one nucleus.

For incorporation of [^3H]-hypoxanthine analysis, [^3H]-hypoxanthine was provided either for 24 hours in a complete medium, or for 4 hours in a partially supplemented medium lacking human plasma and
10 unlabelled hypoxanthine. Uninfected erythrocytes, which do not synthesize either RNA or DNA, do not incorporate [^3H]-hypoxanthine into acid insoluble radioactivity.

The antimalarial activities of various
15 oligonucleotides at $0.1\mu\text{M}$ and $1.0\mu\text{M}$ concentration against the chloroquine resistant *P. falciparum* W2 strain growing nonsynchronously are shown in Table II, below.

-28-

Table II					
Antimalarial activity of oligodeoxynucleotides against chloroquine-resistant <i>Plasmodium falciparum</i> W2 (Indochina strain)					
Oligomer	Concentration (μ M)	Parasitemia (% parasitized red blood cells) R T S			[³ H]hypoxanthine incorporation (% of control)
Experiment 1					
None		1.8	2.8	2.0	100
PSI	0.1	0.8	2.6	1.4	121
PSI	1	0.1	0.5	0.3	31
PSII	0.1	0.9	1.9	1.3	110
PSII	1	-	0.4	0.3	36
POII	1	0.5	1.5	1.7	88
PNII	1	0.7	1.6	1.8	93
RI	0.1	0.7	1.3	1.5	71
RI	1	0.1	-	0.1	18
RII	0.1	1.1	2.3	2.1	115
RII	1	0.6	1.5	1.0	73
Experiment 2					
None		2.1	1.9	2.3	100
PSIII	0.1	0.9	1.7	2.0	85
PSIII	1	0.2	0.6	0.1	36
PSNIII	0.1	0.7	1.1	0.9	76

SUBSTITUTE SHEET

-29-

PSNIII	1	-	0.3	0.2	20
--------	---	---	-----	-----	----

Parasitemia was determined by counting a total of at least 1000 red blood cells. R, T and S represent the count of rings, trophozoites and schizonts, respectively.

The antimalarial activities of various oligonucleotides at 0.1 and 1.0 μ M concentration against the chloroquine resistant *P. falciparum* W2 strain, growing synchronously, are shown in Table III, below.

-30-

Table III					
Antimalarial Effects of Oligodeoxynucleotides Against Chloroquine-Resistant <i>Plasmodium Falciparum</i> W2 in Synchronous Cultures					
Oligomer	Concentration n (μ M)	Parasitemia (% parasitized red blood cells) R T S			[³ H]Hypoxanthine incorporation into schizonts, 72 hrs after D-sorbitol synchronization (% of control)
Experiment 1: 72 hours after synchronization					
None		0.2	2.6	16.1	100
PSI	0.1	0.1	1.0	14.3	154
PSI	1	-	0.5	3.6	43
RI	0.1	0.1	0.6	10.7	68
RI	1	-	0.4	2.5	26
Chloroquine	0.1	-	0.4	0.6	2
Experiment 2: Invasion assay, 24 hours treatment (24-48 hours after synchronization) during schizonts-rings, transitions, with analysis at 48 hours after synchronization					
None		19.0	0.4	-	
PSI	0.1	15.6	1.3	0.1	
PSI	1	5.7	1.2	-	
RI	0.1	10.1	0.9	0.2	
RI	1	3.3	0.9	-	
Chloroquine	0.1	14.8	1.7	0.6	
Experiment 3: Invasion assay, as in Experiment 2 but with different cultures					
None		4.9	0.7	-	

SUBSTITUTE SHEET

-31-

PSIII	0.1	1.6	0.6	-	
PSIII	1	0.6	0.3	-	
PSNIII	0.1	1.2	0.3	-	
PSNIII	1	0.3	0.3	-	

-32-

The fifty percent inhibition concentration (IC_{50}) for various oligonucleotides was determined, and the results are shown for the chloroquine resistant P. falciparum strain W2 (Table IV), as well as for the chloroquine sensitive strain D6 (Table V). Chloroquine was used as a control. For these experiments, parasite cultures were synchronized by D-sorbitol treatment. To examine the effect on schizont to ring transition, antimalarial compounds were added for 24 hours, beginning 24 hours after synchronization. To examine the effect on ring to trophozoite to schizont transitions, antimalarial compounds were added for 24 hours, beginning 48 hours after synchronization. Inhibition was measured by [3H]-hypoxanthine incorporation 72 hours after synchronization.

SUBSTITUTE SHEET

-33-

<p align="center"><u>Table IV</u></p> <p align="center">Antimalarial Activities of Oligodeoxynucleotides Against <u>The Chloroquine-Resistant Plasmodium falciparum W2 strain</u></p>			
Oligomer or Chloroquine (during schizonts to rings transition, 24 to 48 hours after synchronization)	IC ₅₀ (μM)	Oligomer or Chloroquine (during rings to trophozoites to schizonts transition, 48 to 72 hours after synchronization)	IC ₅₀ (μM)
PSI	0.9	PSI	>2.5
PSII	1.1	PSII	>2.5
PSIII	0.7	PSIII	>2.5
PSNIII	0.5	PSNIII	>2.5
RI	0.5	RI	>2.5
RIII	>5.0	RIII	>5.0
RIV	>5.0	RIV	>5.0
Chloroquine	0.065	Chloroquine	0.050

SUBSTITUTE SHEET

-34-

<p align="center"><u>Table V</u></p> <p align="center">Antimalarial Activities of Oligodeoxynucleotides Against The Chloroquine-Sensitive <i>Plasmodium falciparum</i> D6 strain</p>			
Oligomer or Chloroquine (during schizonts to rings transition, 24 to 48 hours after synchronization)	IC ₅₀ (μ M)	Oligomer or Chloroquine (during rings to trophozoites to schizonts transition, 48 to 72 hours after synchroniza- tion)	IC ₅₀ (μ M)
PSI	0.9	PSI	>2.5
PSII	0.9	PSII	>2.5
PSIII	0.8	PSIII	>2.5
PSNIII	0.5	PSNIII	>2.5
RI	0.7	RI	>2.5
RIII	>5.0	RIII	>5.0
RIV	>5.0	RIV	>5.0
Chloroquine	0.015	Chloroquine	0.004

SUBSTITUTE SHEET

-35-

These results indicate that oligonucleotide phosphorothioates are equally effective in inhibiting the growth and invasion of chloroquine resistant and chloroquine sensitive strains of *P. falciparum*. The results shown in Tables IV and V further suggest that the tested oligonucleotides interfere with schizont maturation, merozoite release, merozoite attachment to erythrocytes, merozoite invasion of erythrocytes, or ring formation. This is in contrast to chloroquine, which is a known schizonticidal agent. Although chloroquine inhibited even the chloroquine resistant strain W2 at the high concentrations shown in Table IV, such concentrations cannot be used in vivo because of significant toxic side effects. In contrast, the IC_{50} for oligonucleotides shown in Tables IV and V is at least 50 times lower than the concentration reported to cause toxic effects in rats and mice (see Agrawal, In: Prospects for Antisense Nucleic Acid Therapy of Cancer and AIDS (E. Wickstrom, Ed.), Wiley-Liss, Inc., pp. 143-158 (1990)).

All tested oligonucleotide phosphorothioates having a complementary sequence to segments of the malarial genome exhibited antimalarial activity.

-36-

Interestingly, one of the apparently random oligonucleotides tested showed significant antimalarial activity. The mechanism of this inhibition is not known. Higher antimalarial activity was observed for an oligonucleotide having a butyl phosphoramidate group at the last internucleotide phosphate moiety of the 3' end and (PSNIII) than for an oligonucleotide of identical sequence, but lacking the butyl phosphoramidate group (PSIII). This chemical modification inhibits exonucleolytic degradation of the oligonucleotide, thus giving increased antimalarial activity as a product of increased oligonucleotide stability.

Oligonucleotides were taken up by parasitized erythrocytes, but were not taken up by uninfected erythrocytes (data not shown), suggesting that oligonucleotides can be used for intravascular treatment of infectious diseases in which the only association sought is that of the oligonucleotide with the infected cell. Similar alteration of the permeability functions of a host cell carrying an infectious agent has been described for viral diseases in Virology (Fields and Knips, Eds.) Raven Press, New

-37-

York (1990). This result suggests that oligonucleotides can be used for systemic treatment of pathogenic infections generally, i.e., for parasitic viral and bacterial infections.

-38-

WE CLAIM:

1. A method of inhibiting an active infection by a pathogen, comprising the step of administering an oligonucleotide that inhibits the replication or reproduction of the pathogen.
2. The method according to claim 1, wherein the pathogen is a parasite.
3. The method according to claim 1, wherein the pathogen is a bacterium.
4. The method according to claim 1, wherein the pathogen is a virus.
5. The method according to claim 2, wherein the parasite is selected from the group consisting of malaria, leishmania, schistozoma and trypanosoma.
6. The method according to claim 1, wherein the oligonucleotide has a nucleotide sequence that hybridizes under physiological conditions to a vital gene of the pathogen.

-39-

7. The method according to claim 6, wherein the vital gene is selected from the group consisting of P195 and dihydrofolate reductase-thymidilate synthase, and wherein the pathogen is Plasmodium falciparum.

5 8. The method according to claim 1, wherein the oligonucleotide has one or more modified internucleoside linkage.

 9. The method according to claim 8, wherein the modified internucleoside linkage is a phosphorothioate
10 linkage.

 10. The method according to claim 8, wherein the modified internucleoside linkage is a phosphoroamidate linkage.

 11. The method according to claim 1, wherein the
15 oligonucleotide has a chemical structure at either or both ends to prevent nucleolytic degradation.

-40-

12. The method according to claim 9, wherein the oligonucleotide has a chemical structure at either or both ends to prevent nucleolytic degradation.

13. The method according to claim 10, wherein
5 the oligonucleotide has a chemical structure at either or both ends to prevent nucleolytic degradation.

14. The method according to claim 1, wherein the pathogen is resistant to a conventional chemotherapeutic agent.

10 15. The method according to claim 14, wherein the conventional chemotherapeutic agent is selected from the group consisting of chloroquine, quinine, quinidine, mefloquine and pyrimethamine.

15 16. A method of inhibiting replication or reproduction of a parasite, comprising the step of administering an oligonucleotide having a nucleotide sequence of CTTGGCAGCTGCGCGTGACAT.

-41-

17. The method according to claim 16, wherein the parasite is Plasmodium falciparum.

18. The method according to claim 16, wherein the oligonucleotide is an oligonucleotide
5 phosphorothioate or oligonucleotide phosphorodithioate.

19. A method of inhibiting replication or reproduction of Plasmodium falciparum, comprising the step of administering an oligonucleotide having three
10 to thirty nucleotide residues and a nucleotide sequence that hybridizes under physiological conditions to a vital gene of Plasmodium falciparum.

20. A method according to claim 19, wherein the oligonucleotide has one or more modified
15 internucleoside linkage.

21. A method according to claim 20, wherein the modified internucleoside linkage is a phosphorothioate, phosphorodithioate, or phosphoroamidate linkage.

-42-

22. A method according to claim 19, wherein the oligonucleotide has a chemical structure at either or both ends that renders the oligonucleotide resistant to nucleolytic degradation.

5 23. A method according to claim 20, wherein the oligonucleotide has a chemical structure at either or both ends that renders the oligonucleotide resistant to nucleolytic degradation.

10 24. A method according to claim 19, wherein the oligonucleotide has a nucleotide sequence of TAAAAAGAATATGATCTTCAT.

25. The method according to claim 24, wherein the oligonucleotide has one or more modified internucleotide linkage.

15 26. The method according to claim 25, wherein the modified internucleotide linkage is selected from the group consisting of phosphorothioate, phosphorodithioate, and phosphoramidate.

-43-

27. The method according to claim 25, wherein the oligonucleotide has a chemical structure at either or both ends to prevent nucleolytic degradation.

28. The method according to claim 26, wherein
5 the oligonucleotide has a chemical structure at either or both ends to prevent nucleolytic degradation.

29. A method according to claim 19, wherein the oligonucleotide has a nucleotide sequence of AGCAACTGAGCCACCTGA.

10 30. The method according to claim 29, wherein the oligonucleotide has one or more modified internucleotide linkage.

31. The method according to claim 30, wherein the modified internucleotide linkage is selected from
15 the group consisting of phosphorothioate, phosphorodithioate, and phosphoroamidate.

-44-

32. The method according to claim 29, wherein the oligonucleotide has a chemical structure at either or both ends to prevent nucleolytic degradation.

33. The method according to claim 30, wherein
5 the oligonucleotide has a chemical structure at either or both ends to prevent nucleolytic degradation.

34. A method according to claim 19, wherein the oligonucleotide has a nucleotide sequence of
GTCGCAGACTTGTTCCATCAT.

10 35. The method according to claim 34, wherein the oligonucleotide has one or more modified internucleotide linkage.

36. The method according to claim 35, wherein the modified internucleotide linkage is selected from
15 the group consisting of phosphorothioate, phosphorodithioate, and phosphoroamidate.

-45-

37. The method according to claim 34, wherein the oligonucleotide has a chemical structure at either or both ends to prevent nucleolytic degradation.

38. The method according to claim 35, wherein
5 the oligonucleotide has a chemical structure at either or both ends to prevent nucleolytic degradation.

39. The method according to claim 36, wherein the oligonucleotide has a chemical structure at either or both ends to prevent nucleolytic degradation.

10 40. An antimalarial oligonucleotide having a nucleotide sequence selected from the group consisting of TAAAAAGAATATGATCTTCAT, AGCAACTGAGCCACCTGA, GTCGCAGACTTGTTCCATCAT, and CTTGGCAGCTGCGCGTGACAT.

-46-

41. A method of treating a condition selected from the group consisting of malaria, schistosomiasis, candidiasis, histoplasmosis, cryptococcus, blastomycosis, aspergillosis, sporotrichosis, 5 dermatophytosis, coccidioidomycosis, typhus, Rocky Mountain spotted fever, Chlamydia trachomatis infection, Lymphogranuloma venereum infection, amebiasis, Chagas' disease, toxoplasmosis, pneumocystosis, giardiasis, cryptosporidiosis, 10 trichomoniasis, Pneumocystis carini infections, ascariasis, filariasis, trichinosis, nematode infection and cestode infection, wherein the condition is caused by a drug resistant pathogen.